Modifications of pretreatment therapeutic measures and ascites severity in the 6 patients with MC and decompensated cirrhosis. (A) Mean doses of kanrenone before rituximab therapy (baseline) and at 6 months of follow-up after therapy interruption EOF-U. (B) Mean doses of furosemide before treatment and at EOF-U. (C) Mean doses of albumin infusion before treatment and at EOF-U. (D) Modifications of ascites severity degree according to Arroyo et al²⁵  observed before rituximab (baseline), at the end of therapy (EOT), at 3 months of follow-up (3m.F-U), and at EOF-U.